title: Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
abstract: Graft-versus-tumor effects can be achieved after allogeneic bone marrow transplantation in patients with malignancies of the kidney or hematopoietic system but are often accompanied by severe graft-versus-host-disease (GVHD). We sought to maximize graft-versus-tumor while minimizing GVHD using tumor-specific allogeneic effector T cells rather than open-repertoire T cells. We transferred allogeneic CD8(+) pmel-1 or CD4(+) TRP-1 T cells specific for the melanoma-associated antigens, glycoprotein 100 (gp100) and tyrosinase-related protein-1 (TRP-1), respectively, into B16-melanoma-bearing mice. Mice receiving a preparative regimen of nonmyeloablating (5 Gy) total body irradiation experienced the rapid rejection of tumor-specific allogeneic lymphocytes with no impact on tumor growth. However, when mice were given more intense total body irradiation conditioning regimens combined with autologous bone marrow transplantation, adoptively transferred allogeneic tumor-specific T lymphocytes persisted at detectable levels for several weeks and mediated significant regression of large, vascularized tumors. We found that the risk of GVHD was low when tumor-specific T cells were transferred and significant toxicity was observed only when substantial numbers of open repertoire allogeneic naive T cells were mixed with the tumor-specific lymphocytes. Taken together, these data indicate that the use of tumor-specific allogeneic CD8(+) T cells or CD4(+) can result in significant antitumor effects in the absence of measurable GVHD.
authors.affiliation: Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Andrea
authors.initials: A
authors.lastname: Boni
authors.forename: Pawel
authors.initials: P
authors.lastname: Muranski
authors.forename: Lydie
authors.initials: L
authors.lastname: Cassard
authors.forename: Claudia
authors.initials: C
authors.lastname: Wrzesinski
authors.forename: Chrystal M
authors.initials: CM
authors.lastname: Paulos
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Palmer
authors.forename: Luca
authors.initials: L
authors.lastname: Gattinoni
authors.forename: Christian S
authors.initials: CS
authors.lastname: Hinrichs
authors.forename: Chi-Chao
authors.initials: CC
authors.lastname: Chan
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Restifo
mesh_terms: D019264:Adoptive Transfer / Q000379:methods*; D000818:Animals; D001787:Blood Group Incompatibility / Q000235:genetics / Q000276:immunology*; D002478:Cells, Cultured; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D020350:Graft vs Tumor Effect / Q000235:genetics / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000502:physiology* / Q000637:transplantation*; D008285:Major Histocompatibility Complex / Q000502:physiology*; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D012074:Remission Induction / Q000379:methods; D014184:Transplantation, Homologous / Q000276:immunology / Q000502:physiology; D047368:Tumor Burden / Q000276:immunology
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2346-57
references.pmid: 15800326
references.citation: J Immunother. 2005 May-Jun;28(3):258-67
references.pmid: 15838383
references.citation: Lancet. 2002 Aug 10;360(9331):436-42
references.pmid: 12241714
references.citation: Ann Surg Oncol. 1996 Jan;3(1):67-73
references.pmid: 8770305
references.citation: Immunol Cell Biol. 2008 May-Jun;86(4):312-9
references.pmid: 18362947
references.citation: Lancet Oncol. 2005 May;6(5):344-6
references.pmid: 15863383
references.citation: J Control Release. 2007 Sep 11;122(1):102-10
references.pmid: 17628160
references.citation: J Immunol. 2008 Mar 1;180(5):3122-31
references.pmid: 18292535
references.citation: J Clin Invest. 2005 Jun;115(6):1616-26
references.pmid: 15931392
references.citation: Biol Blood Marrow Transplant. 2008 May;14(5):518-30
references.pmid: 18410894
references.citation: N Engl J Med. 2000 Sep 14;343(11):750-8
references.pmid: 10984562
references.citation: Front Biosci. 2007 May 01;12:2922-34
references.pmid: 17485269
references.citation: J Exp Med. 2005 Oct 3;202(7):907-12
references.pmid: 16203864
references.citation: J Exp Med. 1998 Mar 2;187(5):693-702
references.pmid: 9480979
references.citation: Nat Biotechnol. 2008 Apr;26(4):453-61
references.pmid: 18376399
references.citation: Bone Marrow Transplant. 2002 Jul;30(2):95-102
references.pmid: 12132048
references.citation: Blood. 2004 Feb 15;103(4):1534-41
references.pmid: 14551132
references.citation: Bone Marrow Transplant. 2003 May;31(10):943-5
references.pmid: 12748675
references.citation: Blood. 1992 Jul 15;80(2):551-5
references.pmid: 1627807
references.citation: Exp Hematol. 2000 Nov;28(11):1225-31
references.pmid: 11063870
references.citation: Nat Immunol. 2004 Nov;5(11):1143-8
references.pmid: 15475958
references.citation: Nat Rev Cancer. 2008 Apr;8(4):299-308
references.pmid: 18354418
references.citation: J Clin Oncol. 2004 Oct 1;22(19):3886-92
references.pmid: 15314059
references.citation: Blood. 1995 Mar 1;85(5):1207-14
references.pmid: 7858251
references.citation: Immunol Rev. 2008 Jun;223:334-60
references.pmid: 18613846
references.citation: Blood. 2006 Sep 15;108(6):1797-808
references.pmid: 16741253
references.citation: Nat Clin Pract Oncol. 2006 Dec;3(12):668-81
references.pmid: 17139318
references.citation: Blood. 2007 Oct 15;110(8):2793-802
references.pmid: 17638856
references.citation: Hum Gene Ther. 2005 Jan;16(1):35-48
references.pmid: 15703487
references.citation: Immunol Rev. 2006 Jun;211:214-24
references.pmid: 16824130
references.citation: Cancer Immunol Immunother. 2005 Aug;54(8):721-8
references.pmid: 16010587
references.citation: Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8061-6
references.pmid: 18523011
references.citation: J Immunother. 2003 Jul-Aug;26(4):332-42
references.pmid: 12843795
references.citation: J Immunol. 2008 Jul 1;181(1):165-73
references.pmid: 18566381
references.citation: J Immunol. 1996 Dec 1;157(11):4811-21
references.pmid: 8943383
references.citation: J Immunol. 2005 Nov 15;175(10):7046-52
references.pmid: 16272366
references.citation: Lancet. 2005 Jul 23-29;366(9482):318-20
references.pmid: 16039336
references.citation: Nat Rev Immunol. 2007 Dec;7(12):942-53
references.pmid: 18007679
references.citation: Immunity. 2005 Mar;22(3):371-83
references.pmid: 15780993
references.citation: J Immunother. 2005 Jul-Aug;28(4):281-8
references.pmid: 16000944
references.citation: Curr Opin Hematol. 2007 Nov;14(6):616-24
references.pmid: 17898565
references.citation: Blood. 2008 May 15;111(10):5242-51
references.pmid: 18285547
references.citation: Cancer Immunol Immunother. 2001 Mar;50(1):3-15
references.pmid: 11315507
references.citation: Nat Rev Immunol. 2006 May;6(5):383-93
references.pmid: 16622476
references.citation: J Clin Invest. 2007 Aug;117(8):2197-204
references.pmid: 17657310
references.citation: Lancet. 1996 Aug 17;348(9025):472-3
references.pmid: 8709796
references.citation: Bone Marrow Transplant. 2005 Jun;35(12):1127-32
references.pmid: 15834432
references.citation: J Immunother. 2005 Nov-Dec;28(6):517-24
references.pmid: 16224268
references.citation: Blood. 2008 Jul 15;112(2):362-73
references.pmid: 18354038
references.citation: Blood. 2007 Jun 15;109(12):5168-77
references.pmid: 17353346
references.citation: N Engl J Med. 2003 Jan 16;348(3):255-6
references.pmid: 12529469
references.citation: J Clin Invest. 2007 Feb;117(2):492-501
references.pmid: 17273561
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74
references.pmid: 14762166
references.citation: Bone Marrow Transplant. 2003 Feb;31(4):253-61
references.pmid: 12621459
references.citation: Nat Clin Pract Oncol. 2008 May;5(5):256-67
references.pmid: 18398414
references.citation: J Exp Med. 2003 Aug 18;198(4):569-80
references.pmid: 12925674
references.citation: Hematology Am Soc Hematol Educ Program. 2007;:460-5
references.pmid: 18024665
references.citation: Annu Rev Med. 2004;55:459-75
references.pmid: 14746531
references.citation: Gene Ther. 2007 Mar;14(6):491-502
references.pmid: 17203106
references.citation: J Clin Oncol. 2002 Apr 15;20(8):2017-24
references.pmid: 11956260
references.citation: Trends Immunol. 2008 May;29(5):235-41
references.pmid: 18375183
references.citation: J Cell Mol Med. 2009 Aug;13(8B):1962-1976
references.pmid: 18624776
references.citation: Semin Immunol. 2007 Oct;19(5):318-30
references.pmid: 18023361
references.citation: Transfusion. 2003 Dec;43(12):1667-71
references.pmid: 14641861
references.citation: Nature. 2003 Feb 20;421(6925):852-6
references.pmid: 12594515
references.citation: Pancreas. 2004 Apr;28(3):e65-9
references.pmid: 15084986
references.citation: Blood. 2007 Aug 15;110(4):1123-31
references.pmid: 17468341
references.citation: Nature. 2006 Apr 27;440(7088):1123
references.pmid: 16641981
references.citation: J Clin Invest. 2003 Jul;112(1):101-8
references.pmid: 12840064
references.citation: Science. 2003 Oct 17;302(5644):415-9
references.pmid: 14564000
references.citation: Science. 2003 Apr 11;300(5617):337-9
references.pmid: 12690201
references.citation: Blood. 2008 Apr 15;111(8):4392-402
references.pmid: 17878399
references.citation: J Exp Med. 1996 Mar 1;183(3):725-9
references.pmid: 8642276
references.citation: N Engl J Med. 2008 Jun 19;358(25):2698-703
references.pmid: 18565862